Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

Abstract

Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated <i>HER2</i>-mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Lung01 ClinicalTrials.gov number, NCT03505710.).